ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
40.22
0.00 (0.00%)
May 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 18.96 - 46.48
Open     -
Vol / Avg. 0.00/1.46M
Mkt cap 3.99B
P/E     -
Div/yield     -
EPS -1.15
Shares 100.30M
Beta 3.07
Inst. own 98%
Aug 3, 2015
Q2 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2015
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 13, 2015
ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Release
Apr 14, 2015
ACADIA Pharmaceuticals Inc at Needham Healthcare Conference
Mar 11, 2015
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZIDTM NDA Submission Conference Call - Webcast
Mar 10, 2015
ACADIA Pharmaceuticals Inc at ROTH Conference
Mar 3, 2015
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1009375.00% -77062.50%
Operating margin -1013800.00% -77691.66%
EBITD margin - -77520.00%
Return on average assets -51.62% -35.94%
Return on average equity -54.47% -37.62%
Employees 119 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in neurological and related central nervous system disorders. It has a pipeline of product candidates led by NUPLAZID (pimavanserin), which is in Phase III development as a treatment for Parkinson's disease psychosis.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis Interim Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Roger G. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Lester J. Kaplan Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters